SCHEMBL2408477

SCHEMBL2408477

Cn1cccc1C(=O)NC(c1ccc(C(=O)NO)cc1)C(C)(C)C

nearest known ligand 0.55

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HDAC6 Q9UBN7 12/20 0.55
HDAC8 Q9BY41 8/20 0.55
HDAC1 Q13547 7/20 0.55
HDAC3 O15379 3/20 0.55
HDAC7 Q8WUI4 2/20 0.55
HDAC2 Q92769 2/20 0.55
HDAC10 Q969S8 2/20 0.55
HDAC5 Q9UQL6 2/20 0.55
HDAC4 P56524 1/20 0.55
RAB9A P51151 4/20 0.43
NPC1 O15118 3/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
HDAC11 Q96DB2 1/20 0.41
POLB P06746 1/20 0.38
PKM P14618 1/20 0.38
HPGD P15428 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12280141 1.00 HDAC6 (0.55) HDAC6HDAC8HDAC1HDAC3HDAC7
SCHEMBL2405231 0.90 HDAC6 (0.55) HDAC6HDAC8HDAC1HDAC3HDAC7
SCHEMBL2406129 0.84 HDAC1 (0.63) HDAC6HDAC8HDAC1HDAC3HDAC7
SCHEMBL12279691 0.84 HDAC1 (0.63) HDAC6HDAC8HDAC1HDAC3HDAC7
SCHEMBL2413099 0.83 HDAC6 (0.59) HDAC6HDAC8HDAC1HDAC3HDAC7
SCHEMBL2411609 0.83 HDAC6 (0.59) HDAC6HDAC8HDAC1HDAC3HDAC7
SCHEMBL2410774 0.83 HDAC6 (0.59) HDAC6HDAC8HDAC1HDAC3HDAC7
SCHEMBL12280350 0.82 HDAC6 (0.47) HDAC6HDAC8HDAC1HDAC3HDAC7
SCHEMBL2437288 0.80 HDAC6 (0.58) HDAC6HDAC8HDAC1HDAC3HDAC7
SCHEMBL2410355 0.78 HDAC6 (0.56) HDAC6HDAC8HDAC1HDAC3HDAC7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9382197-B2 Substituted hydroxamic acids and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2016-07-05 US disclosed
US-20140275093-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2014-09-18 US disclosed
US-20110212969-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2011-09-01 US disclosed
US-20110212969-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2011-09-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140275093-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF HDAC6, HDAC10, HDAC1 HDAC6 1/4885HDAC8 15/4885HDAC1 3/4885
US-20110212969-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF HDAC6, HDAC10, HDAC1 HDAC6 1/4885HDAC8 15/4885HDAC1 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.